Topic: Compulsory License
Indian drugmakers Natco and Alembic won permission to export their copies of two on-patent Bayer blockbusters to aid other would-be generics makers.
A tense, months-long pricing standoff escalated late last week as Colombia announced plans to unilaterally move forward with a “public interest” measure that’ll cut the price of Novartis’ chronic myeloid leukemia med Gleevec there by about 45%.
Despite behind-the-scenes pressure to call off its plans to usher in cheap generics of Novartis' cancer drug Gleevec, Colombia says it's ready to take the next step in its pricing fight.
Earlier this week, top lawmakers in the House of Representatives lambasted U.S. trade officials for allegedly pressuring the Colombian government to reject a compulsory license for Novartis’ cancer med Gleevec. Senate peers are also weighing in on the issue and chastising the officials for bad behavior.
Some lawmakers are up in arms after U.S. officials allegedly pressured the Colombian government to nix a compulsory license for Novartis’ cancer med, Gleevec. Now, they’re demanding answers.
Two leaked letters written by a representative of the Embassy of Colombia in Washington, DC, and sent to officials in that country showcase deep tensions over a plan by the government there to issue a compulsory license and allow generics of Novartis’ cancer med Gleevec.